Hyperfine

Hyperfine, Inc. is a groundbreaking health technology company that has redefined brain imaging with its Swoop system - the world's first FDA-cleared portable magnetic resonance (MR) brain imaging system. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine developed the Swoop system to revolutionize patient care through accessible, clinically relevant diagnostic imaging. The Swoop system combines ultra-low-field magnetic resonance technology with proprietary artificial intelligence to enable portable brain imaging. It can be wheeled directly to a patient's bedside, plugged into a standard electrical outlet, and controlled through a wireless tablet. The system produces T1, T2, FLAIR, and DWI (with ADC map) images within minutes. Hyperfine has continued to enhance the Swoop system's capabilities, receiving multiple FDA clearances for software updates that improve image quality across all sequences. The company went public in 2021 and is traded on the Nasdaq under the ticker HYPR. For the third quarter of 2023, Hyperfine reported revenues of USD 2.33 million and sold six commercial Swoop systems. The company is actively managing spending while focusing on innovation, clinical evidence generation, and commercialization.

Key customers and partnerships

Hyperfine has deployed Swoop systems at several major US hospitals, including Yale New Haven Hospital, University of California Irvine Medical Center, and Ohio State University Wexner Medical Center. The company has expanded internationally, with systems installed in countries like Pakistan, Bangladesh, and Uganda through collaborations with organizations like the Bill & Melinda Gates Foundation. Hyperfine is actively expanding its global reach, having appointed distributors in key European markets including France, the UK, and Italy. The company has also entered into a distribution agreement to develop markets in Asia, including India. Hyperfine collaborates with research institutions and is involved in several clinical studies, including an upcoming Alzheimer's feasibility study and the ACTION PMR study for stroke diagnosis and treatment. As of May 2024, Hyperfine announced partnerships to expand into 12 European countries and key Asian markets, significantly broadening its international presence.